Summit Therapeutics (SMMT)
14.98
+0.24 (1.63%)
Upcoming Events
Latest Headlines
Summit Therapeutics (SMMT) Reports In-Line Q2 EPS
July 23, 2026 5:42 PM - StreetInsider
Form 8-K Summit Therapeutics Inc. For: Jul 23
July 23, 2026 4:35 PM - SEC Filing
Form 424B5 Summit Therapeutics Inc.
July 23, 2026 4:34 PM - SEC Filing
Summit Therapeutics: substantial doubt about our ability to continue as a going concern
July 23, 2026 4:25 PM - StreetInsider
Form 10-Q Summit Therapeutics Inc. For: Jun 30
July 23, 2026 4:09 PM - SEC Filing
Form 8-K Summit Therapeutics Inc. For: Jul 23
July 23, 2026 4:08 PM - SEC Filing
Summit Therapeutics posts Q2 loss, reports ivonescimab trial data
July 23, 2026 4:06 PM - StreetInsider
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
July 23, 2026 4:05 PM - BizWire
H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
July 23, 2026 7:10 AM - StreetInsider
Arcus and Summit team up to test kidney cancer drug combo
July 22, 2026 4:30 PM - StreetInsider
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026 4:30 PM - BizWire
Form 8-K Summit Therapeutics Inc. For: Jul 22
July 22, 2026 7:11 AM - SEC Filing
Summit ivonescimab shows OS hazard ratio of 0.76 in lung cancer trial
July 22, 2026 6:30 AM - StreetInsider
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
July 22, 2026 6:30 AM - BizWire
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
July 16, 2026 8:00 AM - BizWire
H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
July 16, 2026 6:48 AM - StreetInsider
H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
July 15, 2026 7:37 AM - StreetInsider
Summit Therapeutics sells antibiotic asset ridinilazole for up to $105M
July 14, 2026 7:00 AM - StreetInsider
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
July 14, 2026 7:00 AM - BizWire
The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
June 25, 2026 11:40 AM - StreetInsider
Summit Therapeutics plc (SMMT) PT Raised to $9.80 at Bernstein SocGen Group
June 22, 2026 6:32 AM - StreetInsider
Form 8-K Summit Therapeutics Inc. For: Jun 10
June 12, 2026 4:12 PM - SEC Filing
Form 4 Summit Therapeutics Inc. For: Jun 12 Filed by: Zanganeh Mahkam
June 12, 2026 2:35 PM - SEC Filing
Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares
June 12, 2026 12:37 PM - StreetInsider
Form 4 Summit Therapeutics Inc. For: Jun 12 Filed by: DUGGAN ROBERT W
June 12, 2026 12:29 PM - SEC Filing
Form 8-K Summit Therapeutics Inc. For: Jun 10
June 11, 2026 7:44 AM - SEC Filing
Form 424B5 Summit Therapeutics Inc.
June 10, 2026 6:02 AM - SEC Filing
Summit Therapeutics announces $500 million stock offering
June 9, 2026 4:47 PM - StreetInsider
Summit Therapeutics Announces Proposed Public Offering of Common Stock
June 9, 2026 4:47 PM - BizWire
Form S-3ASR Summit Therapeutics Inc.
June 9, 2026 4:34 PM - SEC Filing
Form 4 Summit Therapeutics Inc. For: Jun 04 Filed by: DUGGAN ROBERT W
June 4, 2026 6:08 PM - SEC Filing
Form 4 Summit Therapeutics Inc. For: Jun 04 Filed by: Zanganeh Mahkam
June 4, 2026 5:45 PM - SEC Filing
Form 4 Summit Therapeutics Inc. For: Jun 04 Filed by: Soni Manmeet Singh
June 4, 2026 4:41 PM - SEC Filing
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
June 4, 2026 4:30 PM - BizWire
Form 8-K Summit Therapeutics Inc. For: Jun 02
June 3, 2026 8:01 AM - SEC Filing
Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
June 3, 2026 6:51 AM - StreetInsider
Bernstein SocGen Reiterates Underperform Rating on Summit Therapeutics plc (SMMT)
June 1, 2026 8:23 AM - StreetInsider
Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
June 1, 2026 7:55 AM - StreetInsider
Summit Therapeutics (SMMT) Reiterated at Buy by Stifel on HARMONi-6 'Win'
June 1, 2026 7:41 AM - StreetInsider
Form 8-K Summit Therapeutics Inc. For: May 30
June 1, 2026 6:57 AM - SEC Filing
Summit's ivonescimab shows survival benefit in lung cancer trial
June 1, 2026 2:53 AM - StreetInsider
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
May 31, 2026 9:06 AM - BizWire
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
May 30, 2026 8:00 AM - BizWire
Bernstein SocGen Reiterates Underperform Rating on Summit Therapeutics plc (SMMT)
May 26, 2026 9:14 AM - StreetInsider
Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
May 22, 2026 7:28 AM - StreetInsider
H.C. Wainwright Downgrades Summit Therapeutics plc (SMMT) to Neutral
May 22, 2026 6:14 AM - StreetInsider
Citi Opens Cat Call on Summit Therapeutics plc (SMMT)
May 22, 2026 5:02 AM - StreetInsider
Bernstein SocGen Group Starts Summit Therapeutics plc (SMMT) at Underperform
May 21, 2026 4:23 PM - StreetInsider
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 14, 2026 9:15 AM - StreetInsider
Summit Therapeutics plc (SMMT) PT Lowered to $23 at H.C. Wainwright
May 4, 2026 7:28 AM - StreetInsider
Summit Therapeutics plc (SMMT) PT Lowered to $16 at Piper Sandler
May 1, 2026 7:38 AM - StreetInsider
Form 10-Q Summit Therapeutics Inc. For: Mar 31
April 30, 2026 5:01 PM - SEC Filing
Summit Therapeutics (SMMT) Tops Q1 EPS by 4c
April 30, 2026 4:56 PM - StreetInsider
Form 8-K Summit Therapeutics Inc. For: Apr 30
April 30, 2026 4:41 PM - SEC Filing
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
April 30, 2026 4:32 PM - BizWire
Full Article List
